Qiagen (QGEN) has partnered with ID Solutions to improve access to advanced genetic testing tools for cancer research.
The collaboration combines global expertise, automation and manufacturing capabilities to expand the availability of digital polymerase chain reaction tests, which help analyze DNA for scientific studies, Qiagen said Thursday in a statement.
As part of the agreement, ID Solutions of France will develop and supply these digital PCR tests for non-clinical research use on Qiagen's QIAcuity platforms.
Qiagen of the Netherlands plans to commercialize the assay kits in Europe initially with possible expansion into other markets.
Financial details of the collaboration weren't disclosed.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。